At present, viral neuraminidase (NA) is the primary target of medicines for the treatment of influenza but only few inhibitors of this enzyme (NAIs) have been approved to date: oseltamivir, zanamivir, laninamivir, and peramivir (Li et al., 2015). Here, XK is linked to influenza.